108 related articles for article (PubMed ID: 15193685)
1. Triglyceride-rich lipoprotein remnant levels and metabolism: time to adopt these orphan risk factors?
Brinton EA; Nanjee MN; Hopkins PN
J Am Coll Cardiol; 2004 Jun; 43(12):2233-5. PubMed ID: 15193685
[No Abstract] [Full Text] [Related]
2. Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment: a long-term follow-up study.
Sposito AC; Lemos PA; Santos RD; Hueb W; Vinagre CG; Quintella E; Carneiro O; Chapman MJ; Ramires JA; Maranhão RC
J Am Coll Cardiol; 2004 Jun; 43(12):2225-32. PubMed ID: 15193684
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus.
Fukushima H; Sugiyama S; Honda O; Koide S; Nakamura S; Sakamoto T; Yoshimura M; Ogawa H; Fujioka D; Kugiyama K
J Am Coll Cardiol; 2004 Jun; 43(12):2219-24. PubMed ID: 15193683
[TBL] [Abstract][Full Text] [Related]
4. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
5. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial).
Meyers CD; McCarren M; Wong ND; Abraira C; Duckworth WC; Kashyap ML;
Am J Cardiol; 2006 Jul; 98(1):63-5. PubMed ID: 16784922
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of disease: HDL metabolism as a target for novel therapies.
Rader DJ
Nat Clin Pract Cardiovasc Med; 2007 Feb; 4(2):102-9. PubMed ID: 17245404
[TBL] [Abstract][Full Text] [Related]
7. High-density lipoprotein metabolism: potential therapeutic targets.
Davidson MH; Toth PP
Am J Cardiol; 2007 Dec; 100(11 A):n32-40. PubMed ID: 18047851
[TBL] [Abstract][Full Text] [Related]
8. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
9. Rationale for aggressive lipid lowering: evidence from clinical trials.
Farmer JA
Expert Rev Cardiovasc Ther; 2004 May; 2(3):305-9. PubMed ID: 15151477
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
11. Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction.
Davidson MH; Ballantyne CM
Am J Cardiol; 2008 Apr; 101(8A):1B-2B. PubMed ID: 18375235
[No Abstract] [Full Text] [Related]
12. Recent trials of lipid lowering.
Ray KK; Cannon CP; Braunwald E
Int J Clin Pract; 2007 Jul; 61(7):1145-59. PubMed ID: 17577297
[TBL] [Abstract][Full Text] [Related]
13. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
Alagona P
Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
[TBL] [Abstract][Full Text] [Related]
14. Novel insights on high-density lipoprotein in coronary heart disease.
Genest J
Int J Clin Pract Suppl; 2002 Oct; (132):17-22. PubMed ID: 12425359
[No Abstract] [Full Text] [Related]
15. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
16. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of dyslipidemias and its benefits].
Taskinen MR
Duodecim; 1999; 115(10):1138-44. PubMed ID: 11877853
[No Abstract] [Full Text] [Related]
18. Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease.
Barbagallo CM; Rizzo M; Noto D; Frasheri A; Pernice V; Rubino A; Pieri D; Pinto V; Cefalù AB; Giordano C; Notarbartolo A; Averna MR
Metabolism; 2006 May; 55(5):662-8. PubMed ID: 16631444
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl.
Cromwell WC; Otvos JD
Am J Cardiol; 2006 Dec; 98(12):1599-602. PubMed ID: 17145217
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
